Division of Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland.
FMT and Microbial Therapeutics Program, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Cambridge, Massachusetts.
Pediatrics. 2023 Dec 1;152(6). doi: 10.1542/peds.2023-062922.
Fecal microbiota transplantation (FMT) involves the delivery of an entire microbial community from a healthy donor to a recipient with the intention of ameliorating or curing a specific disease. Current evidence strongly supports a role for FMT in the treatment of Clostridiodes difficile infection, with cure rates of approximately 80% to 90%. This success has led to increasing attention for FMT as a potential therapeutic intervention for other conditions associated with disturbances of the intestinal microbiome, including inflammatory bowel diseases, autism spectrum disorder, and obesity. This clinical report endorses the joint society statement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition and is meant to provide the general pediatrician with a broad overview to enable appropriate guidance to families seeking FMT as treatment of a child's condition.
粪便微生物群移植（FMT）涉及将来自健康供体的整个微生物群落传递给接受者，以期改善或治愈特定疾病。目前的证据强烈支持 FMT 在治疗艰难梭菌感染中的作用，其治愈率约为 80%至 90%。这一成功导致人们越来越关注 FMT 作为治疗与肠道微生物组紊乱相关的其他疾病的潜在治疗干预措施，包括炎症性肠病、自闭症谱系障碍和肥胖症。本临床报告认可北美儿科学会、胃肠病学、肝脏病学和营养学学会与欧洲儿科学会、胃肠病学、肝脏病学和营养学学会的联合学会声明，旨在为普通儿科医生提供广泛的概述，以便为寻求 FMT 治疗儿童疾病的家庭提供适当的指导。
